Investigators from Wuhan University Report New Data on Antiarrhythmic Agents (The Potential Anti-arrhythmic Effect of Sglt2 Inhibitors).

A recent study conducted by investigators from Wuhan University in Hubei, China, explores the potential antiarrhythmic effects of sodium-glucose cotransporter type 2 inhibitors (SGLT2i). While SGLT2i drugs were initially used to treat type 2 diabetes, they have shown promise in managing cardiovascular diseases and heart failure. The researchers provide evidence and mechanisms for the antiarrhythmic effects of SGLT2i, focusing on intracellular sodium, metabolism, and autophagy. Although there are currently no prospective studies specifically on the anti-arrhythmic effects of SGLT2i, this research offers valuable insights into their potential benefits. [Extracted from the article]